NYSE:ELAN - Elanco Animal Health Stock Price, Forecast & News

Elanco Animal Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "ELAN."

Elanco Animal Health (NYSE:ELAN) released its quarterly earnings results on Wednesday, November, 6th. The company reported $0.30 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.26 by $0.04. The firm had revenue of $771.30 million for the quarter, compared to the consensus estimate of $765.85 million. Elanco Animal Health had a return on equity of 7.79% and a net margin of 3.04%. The firm's quarterly revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.29 EPS. View Elanco Animal Health's Earnings History.

Elanco Animal Health is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Elanco Animal Health.

Elanco Animal Health updated its FY20 earnings guidance on Friday, January, 10th. The company provided earnings per share guidance of 1.09-1.16 for the period, compared to the Thomson Reuters consensus estimate of $1.22. The company issued revenue guidance of $3.05-3.11 billion, compared to the consensus revenue estimate of $3.13 billion.

10 brokerages have issued 12 month target prices for Elanco Animal Health's shares. Their forecasts range from $28.00 to $36.00. On average, they anticipate Elanco Animal Health's stock price to reach $32.45 in the next year. This suggests a possible upside of 8.2% from the stock's current price. View Analyst Price Targets for Elanco Animal Health.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elanco Animal Health in the last year. There are currently 6 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Elanco Animal Health.

Media stories about ELAN stock have trended positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Elanco Animal Health earned a news sentiment score of 2.9 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Elanco Animal Health.

Elanco Animal Health saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 13,470,000 shares, an increase of 11.2% from the December 15th total of 12,110,000 shares. Based on an average daily trading volume, of 3,770,000 shares, the days-to-cover ratio is presently 3.6 days. Currently, 3.6% of the shares of the company are sold short. View Elanco Animal Health's Current Options Chain.

Some companies that are related to Elanco Animal Health include Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Mylan (MYL) and Bausch Health Companies (BHC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Elanco Animal Health investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Micron Technology (MU), CVS Health (CVS), Walt Disney (DIS), AT&T (T), Honeywell International (HON), UnitedHealth Group (UNH) and Amgen (AMGN).

(ELAN) raised $1.4 billion in an IPO on Thursday, September 20th 2018. The company issued 62,900,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Barclays, BNP PARIBAS, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Cowen, Academy Securities, Drexel Hamilton, Mischler Financial Group, Ramirez and The Williams Capital Group were co-managers.

Elanco Animal Health's stock is owned by many different of institutional and retail investors. Top institutional investors include Artemis Investment Management LLP (0.08%), Heritage Investors Management Corp (0.05%), Three Peaks Capital Management LLC (0.05%), Nisa Investment Advisors LLC (0.03%), State of Alaska Department of Revenue (0.02%) and Diversified Trust Co (0.02%). Company insiders that own Elanco Animal Health stock include David Alan Urbanek, Dawei Li, Deborah Turner Kochevar, Jeffrey N Simmons, John P Bilbrey, Lawrence Erik Kurzius, Michael J Harrington, Michael-Bryant Hicks, R David Hoover, Ramiro Martin Cabral and Todd S Young. View Institutional Ownership Trends for Elanco Animal Health.

ELAN stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, State of Alaska Department of Revenue, Ingalls & Snyder LLC, BKD Wealth Advisors LLC, Diversified Trust Co and Heritage Investors Management Corp. View Insider Buying and Selling for Elanco Animal Health.

ELAN stock was bought by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Nisa Investment Advisors LLC, Three Peaks Capital Management LLC, DNB Asset Management AS, SFE Investment Counsel, New England Research & Management Inc. and First Hawaiian Bank. Company insiders that have bought Elanco Animal Health stock in the last two years include David Alan Urbanek, Dawei Li, Deborah Turner Kochevar, Jeffrey N Simmons, John P Bilbrey, Lawrence Erik Kurzius, Michael J Harrington, Michael-Bryant Hicks, R David Hoover, Ramiro Martin Cabral and Todd S Young. View Insider Buying and Selling for Elanco Animal Health.

Shares of ELAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ELAN stock can currently be purchased for approximately $30.00.

Elanco Animal Health has a market capitalization of $11.19 billion and generates $3.07 billion in revenue each year. The company earns $86.50 million in net income (profit) each year or $1.18 on an earnings per share basis. Elanco Animal Health employs 5,590 workers across the globe.View Additional Information About Elanco Animal Health.

The official website for Elanco Animal Health is http://www.elanco.com/.

Elanco Animal Health's mailing address is 2500 INNOVATION WAY, GREENFIELD IN, 46140. The company can be reached via phone at 877-352-6261.